-
1
-
-
0035666578
-
The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches
-
Lieberman JA, Perkins D, Belger A et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 50(11), 884-897 (2001)
-
(2001)
Biol. Psychiatry
, vol.50
, Issue.11
, pp. 884-897
-
-
Lieberman, J.A.1
Perkins, D.2
Belger, A.3
-
2
-
-
33645922748
-
Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity, and symptoms
-
Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J Psychiatry 163(3), 418-425 (2006)
-
(2006)
Am. J Psychiatry
, vol.163
, Issue.3
, pp. 418-425
-
-
Bowie, C.R.1
Reichenberg, A.2
Patterson, T.L.3
Heaton, R.K.4
Harvey, P.D.5
-
3
-
-
22144432283
-
A systematic review of the prevalence of schizophrenia
-
Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2(5), e141 (2005)
-
(2005)
PLoS Med.
, vol.2
, Issue.5
-
-
Saha, S.1
Chant, D.2
Welham, J.3
McGrath, J.4
-
4
-
-
80054888052
-
The American Psychiatric Association practice guidelines for the treatment of psychiatric disorders
-
American Psychiatric Association Second Edition. American Psychiatric Publishing Inc., Arlington, VA, USA
-
American Psychiatric Association. The American Psychiatric Association practice guidelines for the treatment of psychiatric disorders. In: Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition. American Psychiatric Publishing Inc., Arlington, VA, USA, 565-746 (2006)
-
(2006)
Practice Guideline for the Treatment of Patients with Schizophrenia
, pp. 565-746
-
-
-
5
-
-
0022534163
-
Outcome study of first-episode psychosis. I: Relapse rates after 1 year
-
Rabiner CJ, Wegner JT, Kane JM. Outcome study of first-episode psychosis. I: relapse rates after 1 year. Am. J Psychiatry 143(9), 1155-1158 (1986)
-
(1986)
Am. J Psychiatry
, vol.143
, Issue.9
, pp. 1155-1158
-
-
Rabiner, C.J.1
Wegner, J.T.2
Kane, J.M.3
-
6
-
-
0004050325
-
Treatment of patients with schizophrenia
-
American Psychiatric Association American Psychiatric Association, Arlington, VA, USA
-
American Psychiatric Association. Treatment of patients with schizophrenia. In: Practice Guidelines for the Treatment of Psychiatric Disorders. American Psychiatric Association, Arlington, VA, USA, 249-440 (2004)
-
(2004)
Practice Guidelines for the Treatment of Psychiatric Disorders
, pp. 249-440
-
-
-
7
-
-
78951471427
-
Aripiprazole as adjunctive therapy for patients with major depressive disorder: Overview and implications of clinical trial data
-
Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 25(2), 109-127 (2011)
-
(2011)
CNS Drugs
, vol.25
, Issue.2
, pp. 109-127
-
-
Pae, C.U.1
Forbes, A.2
Patkar, A.A.3
-
8
-
-
58049157203
-
Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis
-
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657), 31-41 (2009)
-
(2009)
Lancet
, vol.373
, Issue.9657
, pp. 31-41
-
-
Leucht, S.1
Corves, C.2
Arbter, D.3
Engel, R.R.4
Li, C.5
Davis, J.M.6
-
9
-
-
50349086333
-
Neuropharmacology of second-generation antipsychotic drugs: A validity of the serotonin-dopamine hypothesis
-
Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog. Brain Res. 172, 199-212 (2008)
-
(2008)
Prog. Brain Res.
, vol.172
, pp. 199-212
-
-
Kuroki, T.1
Nagao, N.2
Nakahara, T.3
-
10
-
-
0037214276
-
Efficacy of newer generation antipsychotics in the treatment of schizophrenia
-
Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28(Suppl. 1), 9-26 (2003)
-
(2003)
Psychoneuroendocrinology
, vol.28
, Issue.SUPPL. 1
, pp. 9-26
-
-
Tandon, R.1
Jibson, M.D.2
-
11
-
-
0032751075
-
Antipsychotic-induced weight gain: A comprehensive research synthesis
-
Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J Psychiatry 156(11), 1686-1696 (1999)
-
(1999)
Am. J Psychiatry
, vol.156
, Issue.11
, pp. 1686-1696
-
-
Allison, D.B.1
Mentore, J.L.2
Heo, M.3
-
12
-
-
79952899018
-
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone
-
Lee SY, Park MH, Patkar AA, Pae CU. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(2), 490-496 (2011)
-
(2011)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.35
, Issue.2
, pp. 490-496
-
-
Lee, S.Y.1
Park, M.H.2
Patkar, A.A.3
Pae, C.U.4
-
13
-
-
77956421518
-
Quetiapine XR: Current status for the treatment of major depressive disorder
-
Pae CU, Sohi MS, Seo HJ et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(7), 1165-1173 (2010)
-
(2010)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.34
, Issue.7
, pp. 1165-1173
-
-
Pae, C.U.1
Sohi, M.S.2
Seo, H.J.3
-
14
-
-
67649322211
-
A review of the safety and tolerability of aripiprazole
-
Pae CU. A review of the safety and tolerability of aripiprazole. Expert Opin. Drug Saf. 8(3), 373-386 (2009)
-
(2009)
Expert Opin. Drug Saf.
, vol.8
, Issue.3
, pp. 373-386
-
-
Pae, C.U.1
-
15
-
-
80054901686
-
Pravastatin as a therapeutic agent for atypical antipsychotic-induced metabolic syndrome in patients with schizophrenia
-
Pae CU. Pravastatin as a therapeutic agent for atypical antipsychotic-induced metabolic syndrome in patients with schizophrenia. CNS Spectr. 13(5), E1 (2008)
-
(2008)
CNS Spectr.
, vol.13
, Issue.5
-
-
Pae, C.U.1
-
16
-
-
0031719842
-
Adverse effects of the atypical antipsychotics
-
Collaborative Working Group on Clinical Trial Evaluations
-
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. J Clin. Psychiatr, 59(Suppl. 12), 17-22 (1998)
-
(1998)
J Clin. Psychiatr
, vol.59
, Issue.SUPPL. 12
, pp. 17-22
-
-
-
17
-
-
9944225707
-
Aripiprazole: A new atypical antipsychotic with a different pharmacological mechanism
-
Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog. Neuropsychopharmacol. Biol. Psychiatry 28(8), 1213-1219 (2004)
-
(2004)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.28
, Issue.8
, pp. 1213-1219
-
-
Naber, D.1
Lambert, M.2
-
18
-
-
1042291227
-
Focus on aripiprazole
-
Green B. Focus on aripiprazole. Curr Med. Res. Opin. 20(2), 207-213 (2004)
-
(2004)
Curr Med. Res. Opin.
, vol.20
, Issue.2
, pp. 207-213
-
-
Green, B.1
-
19
-
-
41949107744
-
Aripiprazole in the treatment of depressive and anxiety disorders: A review of current evidence
-
Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 22(5), 367-388 (2008)
-
(2008)
CNS Drugs
, vol.22
, Issue.5
, pp. 367-388
-
-
Pae, C.U.1
Serretti, A.2
Patkar, A.A.3
Masand, P.S.4
-
20
-
-
0042887023
-
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology
-
Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8), 1400-1411 (2003)
-
(2003)
Neuropsychopharmacology
, vol.28
, Issue.8
, pp. 1400-1411
-
-
Shapiro, D.A.1
Renock, S.2
Arrington, E.3
-
21
-
-
2942610711
-
Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability
-
DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther. 26(5), 649-666 (2004)
-
(2004)
Clin. Ther.
, vol.26
, Issue.5
, pp. 649-666
-
-
Deleon, A.1
Patel, N.C.2
Crismon, M.L.3
-
22
-
-
10744232425
-
Mechanism of new antipsychotic medications: Occupancy is not just antagonism
-
Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch. Gen. Psychiatry 60(10), 974-977 (2003)
-
(2003)
Arch. Gen. Psychiatry
, vol.60
, Issue.10
, pp. 974-977
-
-
Grunder, G.1
Carlsson, A.2
Wong, D.F.3
-
23
-
-
0035658175
-
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: Illustrating their mechanism of action
-
Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin. Psychiatr 62(12), 923-924 (2001)
-
(2001)
J Clin. Psychiatr
, vol.62
, Issue.12
, pp. 923-924
-
-
Stahl, S.M.1
-
24
-
-
34648830603
-
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: A triple tracer PET study
-
Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am. J Psychiatry 164(9), 1411-1417 (2007)
-
(2007)
Am. J Psychiatry
, vol.164
, Issue.9
, pp. 1411-1417
-
-
Mamo, D.1
Graff, A.2
Mizrahi, R.3
Shammi, C.M.4
Romeyer, F.5
Kapur, S.6
-
25
-
-
33845718611
-
Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways
-
Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32(1), 67-77 (2007)
-
(2007)
Neuropsychopharmacology
, vol.32
, Issue.1
, pp. 67-77
-
-
Urban, J.D.1
Vargas, G.A.2
Von Zastrow, M.3
Mailman, R.B.4
-
26
-
-
35348854954
-
Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912
-
Tadori Y, Kitagawa H, Forbes RA, McQuade RD, Stark A, Kikuchi T. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J. Pharmacol. 574(2-3), 103-111 (2007)
-
(2007)
Eur J. Pharmacol.
, vol.574
, Issue.2-3
, pp. 103-111
-
-
Tadori, Y.1
Kitagawa, H.2
Forbes, R.A.3
McQuade, R.D.4
Stark, A.5
Kikuchi, T.6
-
27
-
-
0036089687
-
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
-
Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol. Exp. Ther. 302(1), 381-389 (2002)
-
(2002)
J Pharmacol. Exp. Ther.
, vol.302
, Issue.1
, pp. 381-389
-
-
Burris, K.D.1
Molski, T.F.2
Xu, C.3
-
28
-
-
0037406258
-
Aripiprazole: A new atypical antipsychotic drug
-
Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother. 37(5), 687-694 (2003)
-
(2003)
Ann Pharmacother.
, vol.37
, Issue.5
, pp. 687-694
-
-
Bowles, T.M.1
Levin, G.M.2
-
29
-
-
68349100113
-
Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design
-
Nahata T, Saini TR. Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design. PDA J. Pharm. Sci. Technol. 63(2), 113-122 (2009)
-
(2009)
PDA J. Pharm. Sci. Technol.
, vol.63
, Issue.2
, pp. 113-122
-
-
Nahata, T.1
Saini, T.R.2
-
30
-
-
4344714861
-
Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder
-
Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64(15), 1715-1736 (2004)
-
(2004)
Drugs
, vol.64
, Issue.15
, pp. 1715-1736
-
-
Swainston, H.T.1
Perry, C.M.2
-
32
-
-
1642535375
-
Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers
-
Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin. Pharmacol. 44(2), 179-187 (2004)
-
(2004)
J Clin. Pharmacol.
, vol.44
, Issue.2
, pp. 179-187
-
-
Mallikaarjun, S.1
Salazar, D.E.2
Bramer, S.L.3
-
33
-
-
18944362633
-
Aripiprazole: Pharmacology, efficacy, safety and tolerability
-
Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev. Neurother. 5(3), 297-307 (2005)
-
(2005)
Expert Rev. Neurother.
, vol.5
, Issue.3
, pp. 297-307
-
-
Kinghorn, W.A.1
McEvoy, J.P.2
-
34
-
-
33845713415
-
Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients
-
Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther. Drug Monit. 28(6), 744-749 (2006)
-
(2006)
Ther. Drug Monit.
, vol.28
, Issue.6
, pp. 744-749
-
-
Molden, E.1
Lunde, H.2
Lunder, N.3
Refsum, H.4
-
35
-
-
55749106241
-
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia
-
Findling RL, Robb A, Nyilas M et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am. J Psychiatry 165(11), 1432-1441 (2008)
-
(2008)
Am. J Psychiatry
, vol.165
, Issue.11
, pp. 1432-1441
-
-
Findling, R.L.1
Robb, A.2
Nyilas, M.3
-
36
-
-
0036738786
-
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
-
Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin. Psychiatr, 63(9), 763-771 (2002)
-
(2002)
J Clin. Psychiatr
, vol.63
, Issue.9
, pp. 763-771
-
-
Kane, J.M.1
Carson, W.H.2
Saha, A.R.3
-
37
-
-
0037410337
-
Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials
-
Marder SR, McQuade RD, Stock E et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 61(2-3), 123-136 (2003)
-
(2003)
Schizophr. Res.
, vol.61
, Issue.2-3
, pp. 123-136
-
-
Marder, S.R.1
McQuade, R.D.2
Stock, E.3
-
38
-
-
0038488945
-
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder
-
Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60(7), 681-690 (2003)
-
(2003)
Arch. Gen. Psychiatry
, vol.60
, Issue.7
, pp. 681-690
-
-
Potkin, S.G.1
Saha, A.R.2
Kujawa, M.J.3
-
39
-
-
9144237416
-
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
-
Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J Neuropsychopharmacol. 6(4), 325-337 (2003)
-
(2003)
Int. J Neuropsychopharmacol.
, vol.6
, Issue.4
, pp. 325-337
-
-
Kasper, S.1
Lerman, M.N.2
McQuade, R.D.3
-
40
-
-
0141828595
-
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study
-
Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin. Psychiatr. 64(9), 1048-1056 (2003)
-
(2003)
J Clin. Psychiatr.
, vol.64
, Issue.9
, pp. 1048-1056
-
-
Pigott, T.A.1
Carson, W.H.2
Saha, A.R.3
Torbeyns, A.F.4
Stock, E.G.5
Ingenito, G.G.6
-
41
-
-
34548189418
-
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks
-
Kane JM, Crandall DT, Marcus RN et al. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr. Res. 95(1-3), 143-150 (2007)
-
(2007)
Schizophr. Res.
, vol.95
, Issue.1-3
, pp. 143-150
-
-
Kane, J.M.1
Crandall, D.T.2
Marcus, R.N.3
-
42
-
-
34447117847
-
A multicentre randomized naturalistic open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole (STAR) study
-
Kerwin R, Millet B, Herman E et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 22(7), 433-443 (2007)
-
(2007)
Eur Psychiatry
, vol.22
, Issue.7
, pp. 433-443
-
-
Kerwin, R.1
Millet, B.2
Herman, E.3
-
43
-
-
60349130296
-
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia
-
Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol. Psychiatry 65(6), 510-517 (2009)
-
(2009)
Biol. Psychiatry
, vol.65
, Issue.6
, pp. 510-517
-
-
Fleischhacker, W.W.1
McQuade, R.D.2
Marcus, R.N.3
Archibald, D.4
Swanink, R.5
Carson, W.H.6
-
44
-
-
16644402581
-
A comparison of weight change during treatment with olanzapine or aripiprazole: Results from a randomized, double-blind study
-
McQuade RD, Stock E, Marcus R et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin. Psychiatr, 65(Suppl. 18), 47-56 (2004)
-
(2004)
J Clin. Psychiatr
, vol.65
, Issue.SUPPL. 18
, pp. 47-56
-
-
McQuade, R.D.1
Stock, E.2
Marcus, R.3
-
45
-
-
33750614310
-
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: A 52-week, open-label comparison with olanzapine
-
Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl.) 189(2), 259-266 (2006)
-
(2006)
Psychopharmacology (Berl.)
, vol.189
, Issue.2
, pp. 259-266
-
-
Chrzanowski, W.K.1
Marcus, R.N.2
Torbeyns, A.3
Nyilas, M.4
McQuade, R.D.5
-
46
-
-
72849140996
-
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy
-
Kane JM, Correll CU, Goff DC et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin. Psychiatr, 70(10), 1348-1357 (2009)
-
(2009)
J Clin. Psychiatr
, vol.70
, Issue.10
, pp. 1348-1357
-
-
Kane, J.M.1
Correll, C.U.2
Goff, D.C.3
-
47
-
-
33646818313
-
Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia
-
Horacek J, Bubenikova-Valesova V, Kopecek M et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20(5), 389-409 (2006)
-
(2006)
CNS Drugs
, vol.20
, Issue.5
, pp. 389-409
-
-
Horacek, J.1
Bubenikova-Valesova, V.2
Kopecek, M.3
-
48
-
-
40549094337
-
Intramuscular aripiprazole: A review of its use in the management of agitation in schizophrenia and bipolar i disorder
-
Sanford M, Scott LJ. Intramuscular aripiprazole: a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS Drugs 22(4), 335-352 (2008)
-
(2008)
CNS Drugs
, vol.22
, Issue.4
, pp. 335-352
-
-
Sanford, M.1
Scott, L.J.2
-
49
-
-
33644828946
-
Aripiprazole: Pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia
-
Grunder G, Kungel M, Ebrecht M, Gorocs T, Modell S. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 39(Suppl. 1), S21-S25 (2006)
-
(2006)
Pharmacopsychiatry
, vol.39
, Issue.SUPPL. 1
-
-
Grunder, G.1
Kungel, M.2
Ebrecht, M.3
Gorocs, T.4
Modell, S.5
-
50
-
-
33645053243
-
Use of aripiprazole during late pregnancy in a woman with psychotic illness
-
Mendhekar DN, Sharma JB, Srilakshmi P. Use of aripiprazole during late pregnancy in a woman with psychotic illness. Ann Pharmacother. 40(3), 575 (2006)
-
(2006)
Ann Pharmacother.
, vol.40
, Issue.3
, pp. 575
-
-
Mendhekar, D.N.1
Sharma, J.B.2
Srilakshmi, P.3
-
52
-
-
46749128245
-
Elderly patients with dementia-related symptoms of severe agitation and aggression: Consensus statement on treatment options, clinical trials methodology, and policy
-
Salzman C, Jeste DV, Meyer RE et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin. Psychiatr, 69(6), 889-898 (2008)
-
(2008)
J Clin. Psychiatr
, vol.69
, Issue.6
, pp. 889-898
-
-
Salzman, C.1
Jeste, D.V.2
Meyer, R.E.3
-
53
-
-
25444518037
-
Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: A randomized, placebo-controlled study
-
De Deyn P, Jeste DV, Swanink R et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin. Psychopharmacol. 25(5), 463-467 (2005)
-
(2005)
J Clin. Psychopharmacol.
, vol.25
, Issue.5
, pp. 463-467
-
-
De Deyn, P.1
Jeste, D.V.2
Swanink, R.3
-
54
-
-
37849034448
-
Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: A multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses
-
Mintzer JE, Tune LE, Breder CD et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am. J Geriatr. Psychiatry 15(11), 918-931 (2007)
-
(2007)
Am. J Geriatr. Psychiatry
, vol.15
, Issue.11
, pp. 918-931
-
-
Mintzer, J.E.1
Tune, L.E.2
Breder, C.D.3
-
55
-
-
50349098704
-
A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease
-
Streim JE, Porsteinsson AP, Breder CD et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am. J Geriatr. Psychiatry 16(7), 537-550 (2008)
-
(2008)
Am. J Geriatr. Psychiatry
, vol.16
, Issue.7
, pp. 537-550
-
-
Streim, J.E.1
Porsteinsson, A.P.2
Breder, C.D.3
-
56
-
-
22744449459
-
Pharmacological management of acute agitation
-
Battaglia J. Pharmacological management of acute agitation. Drugs 65(9), 1207-1222 (2005)
-
(2005)
Drugs
, vol.65
, Issue.9
, pp. 1207-1222
-
-
Battaglia, J.1
-
57
-
-
33751247015
-
Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: Sub-analysis of a double-blind study
-
Andrezina R, Marcus RN, Oren DA et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr Med. Res. Opin. 22(11), 2209-2219 (2006)
-
(2006)
Curr Med. Res. Opin.
, vol.22
, Issue.11
, pp. 2209-2219
-
-
Andrezina, R.1
Marcus, R.N.2
Oren, D.A.3
-
58
-
-
33748659860
-
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: A double-blind, placebo-controlled comparison with intramuscular haloperidol
-
Andrezina R, Josiassen RC, Marcus RN et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl.) 188(3), 281-292 (2006)
-
(2006)
Psychopharmacology (Berl.)
, vol.188
, Issue.3
, pp. 281-292
-
-
Andrezina, R.1
Josiassen, R.C.2
Marcus, R.N.3
-
59
-
-
33846852409
-
Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: A randomized, double-blind, placebo-controlled trial
-
Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin. Psychiatr, 68(1), 111-119 (2007)
-
(2007)
J Clin. Psychiatr
, vol.68
, Issue.1
, pp. 111-119
-
-
Tran-Johnson, T.K.1
Sack, D.A.2
Marcus, R.N.3
Auby, P.4
McQuade, R.D.5
Oren, D.A.6
-
60
-
-
57849153895
-
A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia
-
Rappaport SA, Marcus RN, Manos G, McQuade RD, Oren DA. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. J Am. Med. Dir. Assoc. 10(1), 21-27 (2009)
-
(2009)
J Am. Med. Dir. Assoc.
, vol.10
, Issue.1
, pp. 21-27
-
-
Rappaport, S.A.1
Marcus, R.N.2
Manos, G.3
McQuade, R.D.4
Oren, D.A.5
-
61
-
-
38049002952
-
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: A quantitative review of efficacy and safety
-
Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin. Psychiatr, 68(12), 1876-1885 (2007)
-
(2007)
J Clin. Psychiatr
, vol.68
, Issue.12
, pp. 1876-1885
-
-
Citrome, L.1
-
62
-
-
0036244492
-
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia
-
Breier A, Meehan K, Birkett M et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry 59(5), 441-448 (2002)
-
(2002)
Arch. Gen. Psychiatry
, vol.59
, Issue.5
, pp. 441-448
-
-
Breier, A.1
Meehan, K.2
Birkett, M.3
-
63
-
-
0034935303
-
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia
-
Wright P, Birkett M, David SR et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J Psychiatry 158(7), 1149-1151 (2001)
-
(2001)
Am. J Psychiatry
, vol.158
, Issue.7
, pp. 1149-1151
-
-
Wright, P.1
Birkett, M.2
David, S.R.3
-
64
-
-
0034924403
-
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania
-
Meehan K, Zhang F, David S et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin. Psychopharmacol. 21(4), 389-397 (2001)
-
(2001)
J Clin. Psychopharmacol.
, vol.21
, Issue.4
, pp. 389-397
-
-
Meehan, K.1
Zhang, F.2
David, S.3
-
65
-
-
0035012418
-
Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial
-
Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl.) 155(2), 128-134 (2001)
-
(2001)
Psychopharmacology (Berl.)
, vol.155
, Issue.2
, pp. 128-134
-
-
Daniel, D.G.1
Potkin, S.G.2
Reeves, K.R.3
Swift, R.H.4
Harrigan, E.P.5
-
66
-
-
0035121817
-
Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients
-
Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin. Psychiatr. 62(1), 12-18 (2001)
-
(2001)
J Clin. Psychiatr.
, vol.62
, Issue.1
, pp. 12-18
-
-
Lesem, M.D.1
Zajecka, J.M.2
Swift, R.H.3
Reeves, K.R.4
Harrigan, E.P.5
-
67
-
-
84880670865
-
Pharmacokinetic study of once-monthly aripiprazole intramuscular patients with schizophrenia
-
Honolulu, Hawaii, USA, May 14-16
-
Fleischhacker WW, Kane JM, Sancez R et al. Pharmacokinetic study of once-monthly aripiprazole intramuscular patients with schizophrenia. Presented at: 164th Annual Meeting of the American Psychiatric Association. Honolulu, Hawaii, USA, May 14-16 2011
-
(2011)
164th Annual Meeting of the American Psychiatric Association
-
-
Fleischhacker, W.W.1
Kane, J.M.2
Sancez, R.3
-
68
-
-
79958233416
-
A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia
-
Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J Psychiatry 168(6), 603-609 (2011)
-
(2011)
Am. J Psychiatry
, vol.168
, Issue.6
, pp. 603-609
-
-
Tiihonen, J.1
Haukka, J.2
Taylor, M.3
Haddad, P.M.4
Patel, M.X.5
Korhonen, P.6
-
69
-
-
0029051754
-
Cost of relapse in schizophrenia
-
Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr. Bull. 21(3), 419-429 (1995)
-
(1995)
Schizophr. Bull.
, vol.21
, Issue.3
, pp. 419-429
-
-
Weiden, P.J.1
Olfson, M.2
-
70
-
-
34248574727
-
Partial compliance with antipsychotics and its impact on patient outcomes
-
Narasimhan M, Pae CU, Masand N, Masand P. Partial compliance with antipsychotics and its impact on patient outcomes. Int. J.Psychiatry Clin. Prac. 11(2), 102-111 (2007)
-
(2007)
Int. J.Psychiatry Clin. Prac.
, vol.11
, Issue.2
, pp. 102-111
-
-
Narasimhan, M.1
Pae, C.U.2
Masand, N.3
Masand, P.4
-
71
-
-
0343178162
-
Medication noncompliance in schizophrenia: Part I. Assessment
-
Weldon PAZ. Medication noncompliance in schizophrenia: Part I. Assessment. J Pract. Psych. Behav. Health 3, 106-110 (1997)
-
(1997)
J Pract. Psych. Behav. Health
, vol.3
, pp. 106-110
-
-
Weldon, P.A.Z.1
-
72
-
-
0021246009
-
Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches
-
Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin. Psychiatr. 45(5 Pt 2), 50-59 (1984)
-
(1984)
J Clin. Psychiatr.
, vol.45
, Issue.5 PART 2
, pp. 50-59
-
-
Ereshefsky, L.1
Saklad, S.R.2
Jann, M.W.3
Davis, C.M.4
Richards, A.5
Seidel, D.R.6
-
73
-
-
84864405348
-
-
Otsuka Pharmaceutical Co. Ltd
-
Otsuka Pharmaceutical Co., Ltd www.otsuka.co.jp/en/product/
-
-
-
|